Posted by Michael Wonder on 30 Oct 2023
Celltrion USA announces distribution and incorporation of Yuflyma (adalimumab-aaty), a Humira biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs
26 October 2023 - The treatment will be available on CarePartners Specialty Pharmacy Program in late October and will make Yuflyma accessible to over 10 million lives.
Celltrion USA today announced its FDA approved biosimilar, Yuflyma (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs.
